EXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis Breathalyzer
EXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis Breathalyzer
Avalon GloboCare is a commercial-stage company that provides precision diagnostics and clinical laboratory services.On Friday, Avalon GloboCare Corp. (NASDAQ:ALBT) entered into a memorandum of understanding (MOU) with Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer.
上週五，Avalon GloboCare公司（納斯達克股票代碼: ALBT）與納米傳感器診斷技術公司奇臨診斷有限公司簽訂了一份諒解備忘錄（MOU），旨在探討擬議的戰略合作，共同開發基於揮發性有機化合物的納米傳感器大麻口罩呼吸測試儀。
The MOU provides Avalon with a 120-day exclusivity period during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the proposed strategic collaboration.
根據諒解備忘錄，Avalon將獲得爲期120天的排他性期，期間Avalon打算與奇臨診斷進行磋商，並簽署有關擬議戰略合作的最終協議。
Also Read: EXCLUSIVE: Avalon's Lab Services MSO Poised To Commercialize FDA-Registered External Male Catheter Device
另請參閱：獨家報道：Avalon實驗室服務MSO準備將FDA註冊的外部男性導尿管產品商業化。
Avalon GloboCare is a commercial-stage company that provides precision diagnostics and clinical laboratory services.
Avalon GloboCare是一家提供精準診斷和臨床實驗室服務的商業階段公司。
If Avalon and Qi Diagnostics enter into a definitive agreement within the Exclusivity Period, then the proposed collaboration would focus on the initial prototype-enabling stage, which would involve critical research, data collection, software development, and drafting of the prototype design of a breathalyzer that is capable of detecting cannabis.
如果Avalon和奇臨診斷在排他性期內簽訂最終協議，則擬議合作將專注於初始原型啓用階段，其中涉及關鍵研究、數據收集、軟件開發和起草一個能夠檢測大麻的呼吸測試儀原型設計。
Avalon believes that its regulatory expertise, including—but not limited to—its experience with regulatory pathways, clinical trials, and the approval process in the United States, would be beneficial to such collaboration.
Avalon相信其監管專業知識，包括但不限於其在美國監管途徑、臨床試驗和批准流程方面的經驗，將有助於此類合作。
The proposed collaboration with Qi Diagnostics is subject to negotiations during the exclusivity period, during which the company intends to enter into a definitive agreement to develop the breathalyzer.
與奇臨診斷的擬議合作將在排他性期間進行磋商，公司打算最終簽署協議以開發呼吸測試儀。
However, the terms of such a definitive agreement cannot be assured that they will be acceptable to Avalon or Qi Diagnostics.
然而，此類最終協議的條款不能保證會對Avalon或奇臨診斷是可接受的。
Accordingly, Avalon and Qi Diagnostics may not enter into such a definitive agreement during the Exclusivity Period or at all.
根據協議，Avalon和Qi診斷可能在排他性期間或根本上都不得達成此類明確協議。
Price Action: ALBT stock is up 1.38% to $0.205 during the premarket session at the last check on Friday.
股價走勢：ALBt股價在週五最後一次檢查時，在盤前交易中上漲1.38%至0.205美元。
- Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
- 輝瑞瑞氏病毒生物-疫苗獲得年輕成年人批准後，GSK發佈了鼓舞人心的初步數據，顯示在更大人群中使用的潛力。
譯文內容由第三人軟體翻譯。
